<DOC>
	<DOCNO>NCT01899105</DOCNO>
	<brief_summary>This study design investigate effect food relative bioavailability 2 different strength fixed-dose combination lumacaftor ivacaftor tablet formulation .</brief_summary>
	<brief_title>A Phase 1 Study Investigate Food Effect Lumacaftor Combination With Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy male female subject define protocol Subjects weigh &gt; 50 kg Screening History illness condition might confound result study pose additional risk subject upon administration study drug Positive hepatitis B , C , HIV Standard 12lead ECG demonstrate QTc &gt; 450 msec male subject &gt; 480 msec female subject Screening Visit Abnormal renal function define protocol Screening Forced expiratory volume 1 second ( FEV1 ) &lt; 80 % predict Screening Visit Blood donation ( approximately 1 pint [ 500 mL ] ) within 56 day first dose study drug Treatment investigational drug device within 30 day 5 halflives precede first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>